Heart failure & cardiomyopathies
Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
Authors' conclusion
Treatment with tafamidis in ATTR-CM patients results in a significant reduction in SUV retention index, associated with significant benefits for LV and RV function and cardiac biomarkers.
Study context
- Population
- Wild-type ATTR-CM patients treated with tafamidis 61 mg once daily, with 99mTc-DPD scintigraphy and SPECT/CT at baseline and follow-up (median 9.0 months)
- Participants
- 40 patients
- Exposure
- Reduction ≥ median vs Reduction < median
- Reduction ≥ mediann = 20
- Reduction < mediann = 20reference
- Outcome
- Change from baseline to follow-up, reduction ≥ median vs < median
- Follow-up
- Median, 9.0 months (IQR 7.0-10.0)
Main finding
As reported in the abstract
- Significant decrease in standardized uptake value (SUV) retention index (reduction ≥ median)
- P < 0.001
- Benefit in serum NT-proBNP
- P = 0.006
- Benefit in left atrial volume index
- P = 0.038
- Benefit in left ventricular (LV) global longitudinal strain
- P = 0.028
- Benefit in LVEF
- P = 0.027
- Benefit in LV cardiac index
- P = 0.034
- Benefit in RVEF
- P = 0.025
- Benefit in right ventricular (RV) cardiac index
- P = 0.048
Observational data: associations, not effects.
Original publication
Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. Published 7 March 2023. doi:10.
Summarised from the published abstract; every number is checked against it